BioCatalystWatch
ALMSWorkspace / ALMS / OverviewCompany library
Price
Market cap
Next catalystExpected 2026envudeucitinib · Phase 2 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

envudeucitinib

TYK2

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

envudeucitinib

TYK2

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

envudeucitinibenvudeucitinib (envu; formerly ESK-001) — LUMUS

TYK2

PreINDP1P2P3FilingApproved

TYK2

TYK2

PreINDP1P2P3FilingApproved

TYK2

PreINDP1P3FilingApproved
Upcoming / outlook

Lonigutamab

IGF-1R

PreINDP1P2P3FilingApproved

History / paused

envudeucitinib

TYK2

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ALMS PR & News

ALMS SEC archive